lncRNA-protein interactions that predict response to endocrine therapy in HR plus breast cancer

被引：0
|
作者：
Waiters, Kacie D.
Quttina, Maram
Khan, Ashfia F.
Karami, Samaneh
Peidl, Anthony S.
Babajide, Funmi
Bawa-Khalfe, Tasneem
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-5683
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5683
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Mammographic breast density changes with endocrine therapy (ET) in women with hormone receptor positive (HR plus ) breast cancer in a Utah population
    Wei, Mei
    Pappas, Lisa
    Guinto, Emily
    Sweeney, Carol
    Camp, Nicola
    Freer, Phoebe
    Buys, Saundra
    Henry, N. Lynn
    Curtin, Karen
    CANCER RESEARCH, 2020, 80 (04)
  • [42] Breast Cancer: Palbociclib plus endocrine Therapy versus Capecitabine
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (06)
  • [43] Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
    Berruti, Alfredo
    Buttigliero, Consuelo
    Dogliotti, Luigi
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (22): : 2368 - 2368
  • [44] Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
    Gnant, Michael
    Mlineritsch, Brigitte
    Schippinger, Walter
    Luschin-Ebengreuth, Gero
    Poestlberger, Sabine
    Menzel, Christian
    Jakesz, Raimund
    Seifert, Michael
    Hubalek, Michael
    Bjelic-Radisic, Vesna
    Samonigg, Hellmut
    Tausch, Christoph
    Eidtmann, Holger
    Steger, Guenther
    Kwasny, Werner
    Dubsky, Peter
    Fridrik, Michael
    Fitzal, Florian
    Stierer, Michael
    Rucklinger, Ernst
    Greil, Richard
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (07): : 679 - 691
  • [45] Ribociclib plus Endocrine Therapy in Early Breast Cancer REPLY
    Slamon, Dennis
    Yardley, Denise A.
    Hortobagyi, Gabriel
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (23): : 2221 - 2222
  • [46] Mutation analysis using cell-free DNA for endocrine therapy in patients with HR plus metastatic breast cancer
    Sim, Sung Hoon
    Yang, Han Na
    Jeon, Su Yeon
    Lee, Keun Seok
    Park, In Hae
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [47] Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
    Im, S. -A.
    Lu, Y. -S.
    Bardia, A.
    Harbeck, N.
    Colleoni, M.
    Franke, F.
    Chow, L.
    Sohn, J.
    Lee, K. -S.
    Campos-Gomez, S.
    Villanueva-Vazquez, R.
    Jung, K. -H.
    Chakravartty, A.
    Hughes, G.
    Gounaris, I.
    Rodriguez-Lorenc, K.
    Taran, T.
    Hurvitz, S.
    Tripathy, D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (04): : 307 - 316
  • [48] COST-EFFECTIVENESS OF EVEROLIMUS FOR ENDOCRINE RESISTANT HR plus METASTATIC BREAST CANCER
    Liu, M.
    Matter-Walstra, K.
    Szucs, T. D.
    Dedes, K. J.
    BREAST, 2013, 22 : S113 - S114
  • [49] PELP-1 promotes adverse endocrine therapy response in ER plus breast cancer
    Rees, Michael
    Smith, Chris
    Barrett-Lee, Peter
    Hiscox, Stephen
    CANCER RESEARCH, 2018, 78 (13)
  • [50] A text feature-based approach for literature mining of lncRNA-protein interactions
    Li, Ao
    Zang, Qiguang
    Sun, Dongdong
    Wang, Minghui
    NEUROCOMPUTING, 2016, 206 : 73 - 80
12345